Folinic Acid Calcium

The reduced and formylated active form of folate used in oncology rescue therapy and as a specialty supplement folate form. Bypasses the dihydrofolate reductase step blocked by methotrexate and similar antifolate drugs.

Off-white to yellowish crystalline powder. Light- and oxidation-sensitive; requires sealed, light-protective packaging. Oncology dosing is 10 to 200 milligrams per square meter; supplement dosing is 400 to 1000 micrograms.

We supply pharmaceutical-grade and supplement-grade Calcium Folinate from manufacturers in China holding ISO, Halal, Kosher and other certifications relevant to the product and production.

Common market grades include Pharmaceutical Grade meeting USP/BP/EP specifications, Sterile API Grade for injectable oncology preparations, Supplement Grade (FCC compliant), and the L-isomer (Levoleucovorin) for premium pharmaceutical applications.

Bulk and reduced-MOQ shipments. Batch-level COA covering assay, related substances, water content, heavy metals, and microbiology.

Folinic acid (also called leucovorin) is the chemically reduced and formylated form of folate that bypasses the dihydrofolate reductase enzyme step. The compound was developed in the 1950s specifically as a rescue agent for methotrexate-treated cancer patients and has since become an essential medicine in oncology.

Industrial production proceeds by chemical synthesis from folic acid through catalytic hydrogenation followed by formylation. The product is supplied as the calcium salt for stability and is available as the racemic dl mixture or the more expensive pure L-isomer (levoleucovorin).

Listed on the WHO Model List of Essential Medicines for its oncology rescue indication. Listed in USP, BP, EP, and JP pharmacopoeias. Approved by the U.S. FDA, EMA, and equivalent regulators worldwide as a prescription pharmaceutical.

Strategic positioning combines the dominant pharmaceutical oncology application (steady global volume tied to chemotherapy protocols) with a smaller but growing supplement application as an alternative folate form for individuals who cannot or will not use synthetic folic acid.

The 5-FU potentiation indication in colorectal cancer is the single largest oncology volume use, where folinic acid is given with 5-fluorouracil to increase the chemotherapy drug's binding to thymidylate synthase and improve antitumor effect.

• Oncology rescue therapy: rescue of normal tissues from methotrexate toxicity after high-dose methotrexate chemotherapy
• 5-Fluorouracil potentiation in colorectal cancer chemotherapy
• Antidote for folate antagonist overdose (pyrimethamine, trimethoprim)
• Dietary supplements: alternative active folate form for individuals avoiding folic acid
• Megaloblastic anemia treatment when synthetic folic acid is contraindicated
• Clinical nutrition formulations
• Specialty pharmaceutical compounding
• Veterinary oncology preparations